Bone Mineral Density Quantitative Trait Locus 15 (BMND15)

Categories: Bone diseases, Fetal diseases, Genetic diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Bone Mineral Density Quantitative Trait Locus 15

MalaCards integrated aliases for Bone Mineral Density Quantitative Trait Locus 15:

Name: Bone Mineral Density Quantitative Trait Locus 15 57 5 38
Osteoporosis 57 71
Metaphyseal Fracture, Susceptibility to 57
Compression Fracture, Susceptibility to 57
Osteoporosis, Susceptibility to 57
Fractures, Compression 71
Metaphyseal Fractures 5
Metaphyseal Fracture 57
Compression Fracture 57
Bmnd15 57



Autosomal dominant 57


External Ids:

OMIM® 57 613418
MedGen 40 C3150680
SNOMED-CT via HPO 69 64859006
UMLS 71 C0029456 C0521169

Summaries for Bone Mineral Density Quantitative Trait Locus 15

MalaCards based summary: Bone Mineral Density Quantitative Trait Locus 15, also known as osteoporosis, is related to osteoporosis and bone mineral density quantitative trait locus 8, and has symptoms including tremor, back pain and angina pectoris. An important gene associated with Bone Mineral Density Quantitative Trait Locus 15 is MIR2861 (MicroRNA 2861). The drugs Calcium carbonate and Pioglitazone have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and spinal cord, and related phenotype is osteoporosis.

More information from OMIM: 613418

Related Diseases for Bone Mineral Density Quantitative Trait Locus 15

Diseases in the Bone Mineral Density Quantitative Trait Locus 15 family:

Bone Mineral Density Quantitative Trait Locus 4 Bone Mineral Density Quantitative Trait Locus 18
Bone Mineral Density Quantitative Trait Locus 1 Bone Mineral Density Quantitative Trait Locus 2
Bone Mineral Density Quantitative Trait Locus 3 Bone Mineral Density Quantitative Trait Locus 5
Bone Mineral Density Quantitative Trait Locus 6 Bone Mineral Density Quantitative Trait Locus 7
Bone Mineral Density Quantitative Trait Locus 8 Bone Mineral Density Quantitative Trait Locus 9
Bone Mineral Density Quantitative Trait Locus 10 Bone Mineral Density Quantitative Trait Locus 11
Bone Mineral Density Quantitative Trait Locus 12 Bone Mineral Density Quantitative Trait Locus 13
Bone Mineral Density Quantitative Trait Locus 14 Bone Mineral Density Quantitative Trait Locus 16
Bone Mineral Density Quantitative Trait Locus 17

Diseases related to Bone Mineral Density Quantitative Trait Locus 15 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1402)
# Related Disease Score Top Affiliating Genes
1 osteoporosis 31.9 PDLIM4 MIR2861 CALCR
2 bone mineral density quantitative trait locus 8 11.9
3 osteoporosis, juvenile 11.8
4 osteoporosis-pseudoglioma syndrome 11.8
5 glucocorticoid-induced osteoporosis 11.6
6 hajdu-cheney syndrome 11.6
7 nephrolithiasis/osteoporosis, hypophosphatemic, 1 11.5
8 nephrolithiasis/osteoporosis, hypophosphatemic, 2 11.5
9 juvenile primary osteoporosis 11.5
10 bone mineral density quantitative trait locus 18 11.5
11 bone mineral density quantitative trait locus 16 11.4
12 osteoporosis and oculocutaneous hypopigmentation syndrome 11.3
13 osteoporosis, childhood- or juvenile-onset, with developmental delay 11.3
14 bone disease 11.3
15 rickets 11.3
16 premature menopause 11.2
17 dominant hypophosphatemia with nephrolithiasis or osteoporosis 11.1
18 osteoporosis-macrocephaly-blindness-joint hyperlaxity syndrome 11.1
19 hypophosphatemic nephrolithiasis/osteoporosis 11.1
20 nestor-guillermo progeria syndrome 11.1
21 werner syndrome 11.1
22 syndromic x-linked intellectual disability snyder type 11.1
23 geroderma osteodysplasticum 11.1
24 hyperparathyroidism 11.1
25 multicentric osteolysis, nodulosis, and arthropathy 11.1
26 prader-willi habitus, osteopenia, and camptodactyly 11.1
27 winchester syndrome 11.1
28 ehlers-danlos syndrome, classic-like, 2 11.1
29 lrp5-related primary osteoporosis 11.1
30 macroepiphyseal dysplasia with osteoporosis, wrinkled skin, and aged appearance 11.1
31 lysinuric protein intolerance 11.0
32 amino aciduria with mental deficiency, dwarfism, muscular dystrophy, osteoporosis, and acidosis 11.0
33 intellectual developmental disorder, x-linked, syndromic, snyder-robinson type 11.0
34 aromatase deficiency 11.0
35 epiphyseal dysplasia, multiple, with early-onset diabetes mellitus 11.0
36 mucolipidosis iii alpha/beta 11.0
37 conn's syndrome 11.0
38 hyperthyroidism 11.0
39 celiac disease 1 11.0
40 cholangitis, primary sclerosing 11.0
41 cerebrotendinous xanthomatosis 11.0
42 turner syndrome 11.0
43 bone mineral density quantitative trait locus 3 10.9
44 spondyloocular syndrome 10.9
45 cleidocranial dysplasia 1 10.9
46 hyperparathyroidism 1 10.9
47 dyskeratosis congenita, autosomal recessive 1 10.9
48 ehlers-danlos syndrome, kyphoscoliotic type, 1 10.9
49 hyaline fibromatosis syndrome 10.9
50 lichtenstein syndrome 10.9

Graphical network of the top 20 diseases related to Bone Mineral Density Quantitative Trait Locus 15:

Diseases related to Bone Mineral Density Quantitative Trait Locus 15

Symptoms & Phenotypes for Bone Mineral Density Quantitative Trait Locus 15

Human phenotypes related to Bone Mineral Density Quantitative Trait Locus 15:

# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 osteoporosis 30 HP:0000939

Symptoms via clinical synopsis from OMIM®:

57 (Updated 08-Dec-2022)
compression fractures (in homozygotes)
metaphyseal fractures (in homozygotes)

Clinical features from OMIM®:

613418 (Updated 08-Dec-2022)

UMLS symptoms related to Bone Mineral Density Quantitative Trait Locus 15:

tremor; back pain; angina pectoris; sciatica; equilibration disorder; muscle cramp; pelvic pain

Drugs & Therapeutics for Bone Mineral Density Quantitative Trait Locus 15

Drugs for Bone Mineral Density Quantitative Trait Locus 15 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 387)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Calcium carbonate Approved, Investigational Phase 4 471-34-1
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
Hydrocortisone succinate Approved Phase 4 2203-97-6 3643
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 3640 5754
Clobetasol Approved, Experimental, Investigational Phase 4 25122-46-7, 25122-41-2 2791 5311051 32798
Linagliptin Approved Phase 4 668270-12-0 57389748 10096344
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
Tetracycline Approved, Vet_approved, Withdrawn Phase 4 60-54-8 5353990
Bazedoxifene Approved, Investigational Phase 4 198481-32-2 154257
Medroxyprogesterone acetate Approved, Investigational Phase 4 520-85-4, 71-58-9 6279 10631
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
Polyestradiol phosphate Approved Phase 4 28014-46-2
Sodium citrate Approved, Investigational Phase 4 68-04-2 23431961
Potassium citrate Approved, Investigational, Vet_approved Phase 4 866-84-2
17 Strontium ranelate Approved, Withdrawn Phase 4 135459-87-9
Pamidronic acid Approved Phase 4 40391-99-9 4674
Demeclocycline Approved Phase 4 127-33-3 5311063
Racepinephrine Approved, Vet_approved Phase 4 51-43-4, 329-65-7 838 5816
Lactitol Approved, Investigational Phase 4 585-86-4 157355
Tibolone Approved, Investigational Phase 4 5630-53-5 5470 444008
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 11128-99-7, 4474-91-3 172198
Esomeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6, 119141-88-7 9568614 4594
Atorvastatin Approved Phase 4 134523-00-5 60823
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
Gliclazide Approved Phase 4 21187-98-4 3475
Liraglutide Approved Phase 4 204656-20-2 44147092 16134956
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
Abaloparatide Approved, Investigational Phase 4 247062-33-5
Zoledronic acid Approved Phase 4 118072-93-8 68740
Cinacalcet Approved Phase 4 226256-56-0 156419
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
Dolutegravir Approved Phase 4 1051375-16-6 57414794 54726191
Racivir Approved, Investigational Phase 4 143491-57-0, 143491-54-7 60877
Pravastatin Approved Phase 4 81093-37-0 54687
Morphine Approved, Investigational Phase 4 57-27-2 5288826
Ibuprofen Approved Phase 4 15687-27-1 3672
Acetaminophen Approved Phase 4 103-90-2 1983
Acetylsalicylic acid Approved, Vet_approved Phase 4 50-78-2 2244
Naproxen Approved, Vet_approved Phase 4 22204-53-1 156391 1302
Alendronic acid Approved Phase 4 121268-17-5, 66376-36-1 2088
Denosumab Approved Phase 4 615258-40-7
Raloxifene Approved, Investigational Phase 4 82640-04-8, 84449-90-1 5035
Alfacalcidol Approved, Nutraceutical Phase 4 41294-56-8 5282181
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311

Interventional clinical trials:

(show top 50) (show all 1461)
# Name Status NCT ID Phase Drugs
1 Comparación de la Eficacia y Seguridad clínicas de Osteofortil Respecto de Forteo Unknown status NCT01945788 Phase 4 Teriparatide (rDNA origin)
2 Effect of Mechanical Loading With PTH on Cortical Bone Unknown status NCT03232476 Phase 4
3 Generic Zoledronic Acid Versus Original Zoledronic Acid: A Multicenter, Randomized, Open, Paralled-controlled Clinical Postmenopausal Osteoporotic Women Efficacy and Safety Research. Unknown status NCT03158246 Phase 4 Generic Zoledronic Acid;Original Zoledronic Acid
4 Evaluation of the Influence of Alendronate on Wound Healing After Dental Implants in Patients With Osteoporosis Unknown status NCT00727493 Phase 4 alendronate once weekly 70mg;placebo
5 The Assessment of Osteoporosis Treatment in Post-menopausal Women Unknown status NCT03006003 Phase 4 Raloxifene;Alendronate
6 The Treatment of Osteoporosis Using a Combination of Teriparatide (Forteo) and Denosumab Unknown status NCT02130973 Phase 4 Standard Clinical Practice Regimen;Experimental Cyclic Regimen
7 The Efficacy of Denosumab to Reduce Osteoporosis After Spinal Cord Injury Unknown status NCT01983475 Phase 4 Denosumab;Placebo (identical Denosumab volume of normal saline)
8 Maintenance of Vitamin D Sufficiency With Oral Vitamin D Supplementation in Malaysian Women of Malay and Indian Ethnicity With Post Menopausal Osteoporosis Unknown status NCT02389179 Phase 4 Vitamin D3
9 Effects of Omega-3 Fatty Acids on Bone and Frailty Unknown status NCT00634686 Phase 4
10 Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid Unknown status NCT03926377 Phase 4
11 Pharmacodynamics Study to Investigate the Effect of Evogliptin on Bone Metabolism in Healthy Volunteers Unknown status NCT02587975 Phase 4 Evogliptin
12 Multi-centre Clinical Trial on Hormone Replacement Treatment in China Unknown status NCT01698164 Phase 4 estradiol plus MPA;Ximingting Tablet;estradiol plus progesterone
13 A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers Unknown status NCT02429232 Phase 4 Pioglitazone;Linagliptin
14 Pilot Study: Does Preventive Adjacent Level Cement Augmentation Positively Affect Reoperation Rates After Osteoporotic Vertebral Compression Fractures? Unknown status NCT02489825 Phase 4
15 Changes of Bone Metabolic Markers and Bone Mineral Density After Denosumab and/or Teriparatide Treatment in Japanese Osteoporotic Patients Unknown status NCT02156960 Phase 4 Denosumab treatment in osteoporotic patients;Teriparatide treatment in osteoporotic patients;Denosumab and teriparatide treatment in osteoporotic patients
16 A Randomized, Double-blind, Placebo-controlled Study Evaluating the Analgesic Effects of the Gastrolith, in Osteoporotic Patients Suffering From Recent Skeletal Pain Caused by Vertebral Fractures Unknown status NCT01482858 Phase 4
17 Comparisons of the Effect of Inactive and Active Vitamin D on Serum Sclerostin/dickkopf1 Levels Unknown status NCT01765010 Phase 4 Calcitriol;Alfacalcidol;Cholecalciferol;Placebo
18 A Multi Centre, Randomised, Open Label, Cross-over Study to Evaluate the Percentage of False Negative Osteoporosis Diagnosis's Using the Standard Case-finding Procedure as Described by the Dutch Institute for Healthcare (CBO) and to Determine the Preference of Adult Osteoporosis Patients Between Once Monthly Dosing of Ibandronate (150 mg) and Once Weekly Dosing of Alendronate (70 mg) Completed NCT00327990 Phase 4 Ibandronate;Alendronate
19 A Prospective Open-Label, Multicenter Study to Evaluate the Change in Bone Turnover Markers After Once Monthly Oral Ibandronate Therapy in Treatment Naive Postmenopausal Osteoporosis Patients Completed NCT02598934 Phase 4 Ibandronate
20 Randomized, Open-label, Multi-center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once Monthly Ibandronate and Once Weekly Risedronate. A Six Month, Two-sequence and Two-period Crossover Study. Completed NCT00377234 Phase 4 Risedronate;ibandronate [Bonviva/Boniva]
21 The Effects of Teriparatide on Bone Microarchitecture as Determined by High Resolution Magnetic Resonance Imaging and Digital Topological Analysis Completed NCT00557310 Phase 4 teriparatide
22 A Randomized, Open-label Study to Investigate the Impact of Bone Marker Feedback on Persistence to Once Monthly Oral Bonviva (Ibandronate) Treatment for Post-menopausal Osteoporosis. Completed NCT00545480 Phase 4 ibandronate [Bonviva/Boniva]
23 A Prospective, Open-Label, Multi-Center, Two-Part Study to Investigate Patient Satisfaction With Monthly Dosed Ibandronate Therapy in Women With Post-Menopausal Osteoporosis or Osteopenia Transitioned From Once-Weekly Alendronate or Risendronate Completed NCT02604836 Phase 4 Ibandronate
24 An Open-Label, Multi-Center Study to Determine Level of Adherence to Monthly Oral or Every Three Month Intravenous Ibandronate Treatment in Post-Menopausal Women With Osteoporosis or Osteopenia, Who Are GI Intolerant of Daily or Weekly Alendronate or Risendronate Completed NCT02598453 Phase 4 Ibandronate
25 A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study Completed NCT02598440 Phase 4 Alendronate;Ibandronate
26 A Multicenter, Prospective, Randomized, 2-Way Crossover, Open-Label Phase IV Study in Postmenopausal Women With Osteoporosis Examining Subject Satisfaction and Compliance When Actonel(Rosedronate) is Administered 35mg Once a Week or 5mg Completed NCT00549965 Phase 4 Risedronate Sodium
27 A Multicenter, Prospective, Randomized, 2-Way Crossover, Open-Label Study pn Postmenopausal Women With Osteoporosis Examining Subject Satisfaction and Compliance When Risedronate Sodium (Actonel) in Administered 35mg Once a Week or 5mg Once Daily Completed NCT00453492 Phase 4 risedronate sodium
28 A One-Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Efficacy and Safety of 35-mg Risedronate Administered Once a Week in the Prevention of Osteoporosis in Postmenopausal Women Completed NCT00402441 Phase 4 Risedronate (HMR4003)
29 Investigation of the Effects of Bisphosphonate on the Gingival Crevicular Fluid Levels of Sclerostin and the DKK-1 in Individuals With Postmenopausal Osteoporosis With Periodontal Changes Completed NCT04149405 Phase 4 Bisphosphonate therapy
30 A Randomized Open-Label Study to Investigate the Impact of Bone Marker Feedback at 3 Months on Adherence to Monthly Oral Bonviva in Women With Post-Menopausal Osteoporosis Supported by a Patient Relationship Program Completed NCT00545363 Phase 4 Ibandronate
31 Multicenter and Prospective Study to Determine the Satisfaction With Actonel (Risedronate Sodium) 35mg Once a Week Using Biochemical Markers of Bone as a Control, in Postmenopausal Women With Osteoporosis Completed NCT00632216 Phase 4 Risedronate Sodium
32 ZEST II for Osteoporotic Fracture Prevention Completed NCT02589600 Phase 4 Zoledronic acid
33 A Prospective, Randomized, Open-label, Active-controlled Study to Evaluate the Efficacy and Safety of Fosamax Plus D in Postmenopausal Osteoporotic Women Completed NCT00729651 Phase 4 alendronate sodium (+) cholecalciferol;Comparator: Alendronate sodium (Fosamax)
34 Multi-centre, Randomized, Open Label Trial to Evaluate the Effects of Switching to Bazedoxifene in Comparison With Switching to Calcium and Vitamin D in Postmenopausal Women Previously Treated With Bisphosphonates Completed NCT02090400 Phase 4 Bazedoxifene;Calcium/Vit D
35 Open Label, Parallel Group, Multicenter Study of Two Intravenous (IV) Ibandronate Dose Regimens (2 mg Every 2 Months and 3 mg Every 3 Months) in Women With Postmenopausal Osteoporosis Who Completed Trial BM16550 Completed NCT00551174 Phase 4 ibandronate [Bonviva/Boniva]
36 Bone Marker Changes In One Month Treatment With TERIPARATIDE (LY333334) Injections (rDNA Origin) in Men and Postmenopausal Women With Severe Osteoporosis Completed NCT00532545 Phase 4 Teriparatide
37 A Randomized, Open Label Study Evaluating the Effect on Renal Function of Intravenous Bonviva Given by Injection or Infusion, Compared With Oral Alendronate, in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease. Completed NCT00503113 Phase 4 ibandronate [Bonviva/Boniva];Alendronate
38 Pearlium®/Effecti-Cal®, a Novel Formulation of Calcium, Vitamin D and Minerals for Prevention of Postmenopausal Bone Loss Completed NCT04609189 Phase 4 Pearlium/EffectiCal;Calcium carbonate/vitamin D3
39 A Study of Prevention and Treatment of Postmenopausal Osteoporosis in Chinese Women Completed NCT00860964 Phase 4 Placebo;estradiol valerate
40 Teriparatide and Risedronate in the Treatment of Patients With Severe Postmenopausal Osteoporosis: Comparative Effects on Vertebral Fractures Completed NCT01709110 Phase 4 Teriparatide;Risedronate;Placebo;Calcium;Vitamin D
41 A Randomised, Open Label Study to Investigate the Impact of Bone Marker Feedback at 2 Months on Adherence to Monthly Oral Bonviva (Ibandronate) in Women With Post-menopausal Osteoporosis. Completed NCT00545909 Phase 4 ibandronate [Bonviva/Boniva]
42 Impact of NTx Point of Care (POC) Device on Patient Satisfication With Actonel 35mg Once a Seek Treatment a Multicenter Prospective Open Label Randomized Controlled Community Practice-based Study Completed NCT00549068 Phase 4 Risedronate Sodium (Actonel)
43 An Open-label, Clinical Observation Extension Study to Assess Continuing Safety and Adherence in Patients With Postmenopausal Osteoporosis Receiving Monthly Oral Bonviva Completed NCT00545090 Phase 4 ibandronate [Bonviva/Boniva]
44 A Randomized, Double-blind Study to Evaluate the Effect of Once Monthly Bonviva on Lumbar Bone Mineral Density in the Prevention of Glucocorticoid-induced Osteoporosis in Post-menopausal Women Completed NCT00545051 Phase 4 Placebo;ibandronate
45 Long-Term Effects of Raloxifene Treatment on Bone Quality: A Cross-Sectional Study of Postmenopausal Women With Osteoporosis Previously Enrolled in the Continuing Outcomes Relevant to Evista Study Completed NCT00532428 Phase 4 Raloxifene;Placebo
46 A Study of Carotid Artery Intima-Media Thickness Following Exposure to Raloxifene HCl or Placebo Completed NCT00532246 Phase 4 raloxifene;Placebo
47 An Open-label, Multi-centre, Randomized Study to Investigate Patient Preference on Dosing in the Once-monthly Ibandronate and the Once-weekly Risedronate in Korean Women With Postmenopausal Osteoporosis. A Six-month, Two-sequence, and Two Period Crossover Study Completed NCT00405392 Phase 4 Ibandronate (SB743830HD)
48 Double-blind, Partially Randomized, Parallel Group, Multicenter Study to Assess the Efficacy and Safety of 100 mg and 150 mg Monthly Oral Ibandronate in Women With Postmenopausal Osteoporosis Having Completed the Phase III Oral Ibandronate Trial BM16549 Completed NCT00081653 Phase 4 ibandronate [Bonviva/Boniva]
49 Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis Completed NCT00035256 Phase 4 teriparatide;raloxifene HCl;placebo
50 Skeletal Histomorphometry in Patients on Teriparatide or Zoledronic Acid Therapy Completed NCT00927186 Phase 4 Teriparatide;Zoledronic Acid

Search NIH Clinical Center for Bone Mineral Density Quantitative Trait Locus 15

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Medium chain triglycerides

Genetic Tests for Bone Mineral Density Quantitative Trait Locus 15

Anatomical Context for Bone Mineral Density Quantitative Trait Locus 15

Organs/tissues related to Bone Mineral Density Quantitative Trait Locus 15:

MalaCards : Bone, Bone Marrow, Spinal Cord, Breast, Prostate, Kidney, Liver

Publications for Bone Mineral Density Quantitative Trait Locus 15

Articles related to Bone Mineral Density Quantitative Trait Locus 15:

(show top 50) (show all 32486)
# Title Authors PMID Year
A novel microRNA targeting HDAC5 regulates osteoblast differentiation in mice and contributes to primary osteoporosis in humans. 62 57 5
19920351 2009
Association of genetic variation of the RIL gene, encoding a PDZ-LIM domain protein and localized in 5q31.1, with low bone mineral density in adult Japanese women. 5
12908099 2003
Calcitonin receptor polymorphism is associated with a decreased fracture risk in post-menopausal women. 5
9817931 1998
Allelic variants of human calcitonin receptor: distribution and association with bone mass in postmenopausal Italian women. 5
9571205 1998
Allelic variants of human calcitonin receptor in the Japanese population. 5
9003491 1997
Ambient air pollution, bone mineral density and osteoporosis: Results from a national population-based cohort study. 62
36244420 2023
Emerging Role of 18F-NaF PET/Computed Tomographic Imaging in Osteoporosis: A Potential Upgrade to the Osteoporosis Toolbox. 62
36442958 2023
A biomimetic and bioactive scaffold with intelligently pulsatile teriparatide delivery for local and systemic osteoporosis regeneration. 62
35441117 2023
Dietary interventions for better management of osteoporosis: An overview. 62
34251926 2023
Equol exerts a protective effect on postmenopausal osteoporosis by upregulating OPG/RANKL pathway. 62
36288653 2023
Osteoporosis and sarcopenia are associated with each other and reduced IGF1 levels are a risk for both diseases in the very old elderly. 62
36182103 2023
Er-Xian decoction attenuates ovariectomy-induced osteoporosis by modulating fatty acid metabolism and IGF1/PI3K/AKT signaling pathway. 62
36252878 2023
Real-world effectiveness of anti-osteoporosis medications for the prevention of incident hip and clinical vertebral fractures in patients on long-term glucocorticoid therapy: A nationwide health insurance claims database study in Japan. 62
36347433 2023
Patient experience of telemedicine for osteoporosis care during the COVID-19 pandemic. 62
34914125 2023
The Role of the Pharmacist in Patient Self-Advocacy for Osteoporosis Screening. 62
36461141 2022
Medical optimization of osteoporosis for adult spinal deformity surgery: a state-of-the-art evidence-based review of current pharmacotherapy. 62
36454531 2022
Asynchronous calibration of quantitative computed tomography bone mineral density assessment for opportunistic osteoporosis screening: phantom-based validation and parameter influence evaluation. 62
36456574 2022
The causal association of sarcopenia with osteoporosis and obesity: a Mendelian randomization analysis. 62
36469086 2022
Bone-Targeted delivery of senolytics to eliminate senescent cells increases bone formation in senile osteoporosis. 62
36470392 2022
High prevalence and risk factors for osteoporosis in 1839 patients with systemic sclerosis: a systematic review and meta-analysis. 62
36474110 2022
Prebiotics improve osteoporosis indicators in a preclinical model: systematic review with meta-analysis. 62
36474436 2022
Abaloparatide Improves Rotator Cuff Healing Via Anabolic Effects on Bone Remodeling in a Chronic Rotator Cuff Tear Model of Rat With Osteoporosis: A Comparison With Denosumab: Response. 62
36468703 2022
Isoorientin ameliorates osteoporosis and oxidative stress in postmenopausal rats. 62
36382865 2022
Conversion of osteoporotic vertebral fracture severity score to osteoporosis T-score equivalent status: a framework and a comparative study of Hong Kong Chinese and Rome Caucasian older women. 62
36462068 2022
The prevalence and treatment of osteoporosis in patients undergoing total hip arthroplasty and the levels of biochemical markers of bone turnover. 62
36464500 2022
AKT/GSK3β/NFATc1 and ROS signal axes are involved in AZD1390-mediated inhibitory effects on osteoclast and OVX-induced osteoporosis. 62
36327872 2022
Intervention thresholds and diagnostic thresholds in the management of osteoporosis. 62
36344804 2022
A hypoxia-driven occurrence of chronic kidney disease and osteoporosis in COPD individuals: New insights into environmental cadmium exposure. 62
36265524 2022
SDH5 down-regulation mitigates the damage of osteoporosis via inhibiting the MyD88/NF-κB signaling pathway. 62
36326104 2022
Teff Grain-Based Functional Food for Prevention of Osteoporosis: Sensory Evaluation and Molecular Docking Approach. 62
36094586 2022
Effectiveness of Pharmacological Interventions for Treatment of Osteoporosis in Patients With CKD 3-5D: No Clear Choices. 62
36328907 2022
Corrigendum to "MicroRNA-874 targeting SUFU involves in osteoblast proliferation and differentiation in osteoporosis rats through the Hedgehog signaling pathway" [Biochem. Biophys. Res. Commun. 506(1) (2018) 194-203]. 62
36336525 2022
The prevalence of patients treated for osteoporosis in Greenland is low compared to Denmark. 62
35603589 2022
Romosozumab successfully regulated progressive osteoporosis in a patient with autosomal dominant polycystic kidney disease undergoing hemodialysis. 62
35980440 2022
Advances in Diagnosis and Management of Childhood Osteoporosis 62
35984229 2022
Feasibility of assessing male osteoporosis using MRI IDEAL-IQ sequence of proximal femur in prostate cancer patients. 62
35997228 2022
Dual-energy X-ray absorptiometry (DXA) to measure bone mineral density (BMD) for diagnosis of osteoporosis - experimental data from artificial vertebrae confirms significant dependence on bone size. 62
35937936 2022
Two-year risedronate treatment for osteoporosis in patients with esophageal varices: a non-randomized clinical trial. 62
35767173 2022
Positive programming of the GC-IGF1 axis mediates adult osteoporosis susceptibility in male offspring rats induced by prenatal dexamethasone exposure. 62
36174767 2022
Pterostilbene-isothiocyanate impedes RANK/TRAF6 interaction to inhibit osteoclastogenesis, promoting osteogenesis in vitro and alleviating glucocorticoid induced osteoporosis in rats. 62
36209841 2022
Kefir peptides ameliorate osteoporosis in AKR1A1 knockout mice with vitamin C deficiency by promoting osteoblastogenesis and inhibiting osteoclastogenesis. 62
36252352 2022
Single-cell RNA sequencing analysis dissected the osteo-immunology microenvironment and revealed key regulators in osteoporosis. 62
36257255 2022
Comparison of postoperative outcomes in patients with and without osteoporosis undergoing single-level anterior cervical discectomy and fusion. 62
36299450 2022
Effectiveness of Pharmacological Interventions Versus Placebo or No Treatment for Osteoporosis in Patients With CKD Stages 3-5D: Editorial Summary of a Cochrane Review. 62
36328908 2022
A comparison of different exercise intensities for improving bone mineral density in postmenopausal women with osteoporosis: A systematic review and meta-analysis. 62
36310762 2022
The miRNA-144-5p/IRS1/AKT axis regulates the migration, proliferation, and mineralization of osteoblasts: A mechanism of bone repair in diabetic osteoporosis. 62
36168858 2022
Response letter to "sarcopenia, osteoporosis and fractures: what we see". 62
36469084 2022
Sarcopenia, osteoporosis, and fractures: what we see mainly depends on how we look? 62
36469085 2022
[Retracted] miR‑29b enhances the proliferation and migration of bone marrow mesenchymal stem cells in rats with castration‑induced osteoporosis through the PI3K/AKT and TGF‑β/Smad signaling pathways. 62
36382095 2022
[Osteoporosis: diagnostics and treatment]. 62
36445487 2022

Variations for Bone Mineral Density Quantitative Trait Locus 15

ClinVar genetic disease variations for Bone Mineral Density Quantitative Trait Locus 15:

# Gene Name Type Significance ClinVarId dbSNP ID Position
1 LOC113839511, MIR2861 NR_036055.1(MIR2861):n.33C>G SNV Association
106 rs794728003 GRCh37: 9:130548229-130548229
GRCh38: 9:127785950-127785950
2 PDLIM4 NC_000005.10:g.132251371C>T SNV Risk Factor
6348 GRCh37: 5:131587064-131587064
GRCh38: 5:132251371-132251371
3 CALCR NM_001742.4(CALCR):c.1340T>C (p.Leu447Pro) SNV Risk Factor
17636 rs1801197 GRCh37: 7:93055753-93055753
GRCh38: 7:93426441-93426441
4 TRPV6 NM_018646.6(TRPV6):c.1978G>C (p.Gly660Arg) SNV Likely Pathogenic
818220 rs780306040 GRCh37: 7:142570162-142570162
GRCh38: 7:142872409-142872409

Expression for Bone Mineral Density Quantitative Trait Locus 15

Search GEO for disease gene expression data for Bone Mineral Density Quantitative Trait Locus 15.

Pathways for Bone Mineral Density Quantitative Trait Locus 15

GO Terms for Bone Mineral Density Quantitative Trait Locus 15

Sources for Bone Mineral Density Quantitative Trait Locus 15

8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
27 GO
28 GTR
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
36 LifeMap
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....